ISSN 1006-298X      CN 32-1425/R

导航

肾脏病与透析肾移植杂志 ›› 2018, Vol. 27 ›› Issue (4): 379-382.DOI: 10.3969/j.issn.1006-298X.2018.04.018

• 论文 • 上一篇    下一篇

免疫调节剂治疗系统性轻链型淀粉样变性

  

  • 出版日期:2018-08-28 发布日期:2018-08-31

Current status of immunomodulatory drugs in treatment of sytematic light chain amyloidosis

  • Online:2018-08-28 Published:2018-08-31

摘要:

系统性轻链型淀粉样变性(AL淀粉样变性)是最常见的系统性淀粉样变性。目前AL淀粉样变性的治疗尚无统一的标准,方案选择主要取决于患者病情严重程度。研究显示,免疫调节剂(IMiDs)通过多种机制发挥抗肿瘤作用,在初治及复发难治性AL淀粉样变性的治疗中均有一定的疗效。本文将对临床常用的沙利度胺、来那度胺及泊马度胺等三种IMiDs在AL淀粉样变性治疗中的现状与进展进行综述,为临床治疗提供参考。

 

关键词: 免疫调节剂, 系统性轻链型淀粉样变性, 治疗

Abstract:

Systematic light chain amyloidosis (AL amyloidosis) is the most common of the systemic amyloidosis.There is no treatment standard yet.The choice of treatment mainly depends on the severity of the disease.Immunomodulatory drugs (IMiDs) exert antitumor effect via several mechanism and play a role in the newly diagnosed as well as the relapsed/refractory patients.In this review,we will focuse on the use of the three IMiDs (thalidomide,lenalidomide and pomalidomide) in the treatment of AL amyloidosis.

Key words: immunomodulatory drugs, systematic light chain , amyloidosis, treatment